IFP Advisors’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $807 | Sell |
74
-172
| -70% | -$2.15K | ﹤0.01% | 4283 |
|
|
2025
Q4 | $3.18K | Sell |
246
-28
| -10% | -$359 | ﹤0.01% | 3649 |
|
|
2025
Q3 | $3.54K | Sell |
274
-437
| -61% | -$5.84K | ﹤0.01% | 3445 |
|
|
2025
Q2 | $12.7K | Buy |
711
+250
| +54% | +$4.36K | ﹤0.01% | 2787 |
|
|
2025
Q1 | $8.21K | Sell |
461
-15
| -3% | -$341 | ﹤0.01% | 2651 |
|
|
2024
Q4 | $14.2K | Buy |
476
+17
| +4% | +$360 | ﹤0.01% | 2402 |
|
|
2024
Q3 | $7.17K | Sell |
459
-42
| -8% | -$762 | ﹤0.01% | 2548 |
|
|
2024
Q2 | $8.58K | Hold |
501
| – | – | ﹤0.01% | 2389 |
|
|
2024
Q1 | $7.83K | Sell |
501
-89
| -15% | -$1.31K | ﹤0.01% | 2321 |
|
|
2023
Q4 | $8.81K | Buy |
590
+460
| +354% | +$6.16K | ﹤0.01% | 2235 |
|
|
2023
Q3 | $2.1K | Buy |
130
+49
| +60% | +$1.41K | ﹤0.01% | 2826 |
|
|
2023
Q2 | $3.36K | Sell |
81
-1,305
| -94% | -$81K | ﹤0.01% | 2681 |
|
|
2023
Q1 | $44.3K | Sell |
1,386
-2,175
| -61% | -$174K | ﹤0.01% | 1641 |
|
|
2022
Q4 | $123K | Buy |
3,561
+18
| +0.5% | +$1.35K | ﹤0.01% | 1634 |
|
|
2022
Q3 | $121K | Buy |
3,543
+12
| +0.3% | +$936 | ﹤0.01% | 1721 |
|
|
2022
Q2 | $120K | Hold |
3,531
| – | – | ﹤0.01% | 1575 |
|
|
2022
Q1 | $120K | Buy |
3,531
+1,331
| +61% | +$98K | ﹤0.01% | 1575 |
|
|
2021
Q4 | $169K | Buy |
2,200
+181
| +9% | +$18.2K | ﹤0.01% | 1034 |
|
|
2021
Q3 | $236K | Sell |
2,019
-3
| -0.1% | -$454 | ﹤0.01% | 880 |
|
|
2021
Q2 | $449K | Sell |
2,022
-40
| -2% | -$7.78K | 0.01% | 579 |
|
|
2021
Q1 | $273K | Sell |
2,062
-378
| -15% | -$59.8K | 0.01% | 711 |
|
|
2020
Q4 | $421K | Buy |
2,440
+579
| +31% | +$79.2K | 0.02% | 556 |
|
|
2020
Q3 | $204K | Sell |
1,861
-110
| -6% | -$8.8K | 0.01% | 695 |
|
|
2020
Q2 | $116K | Buy |
1,971
+149
| +8% | +$9.8K | 0.01% | 866 |
|
|
2020
Q1 | $125K | Buy |
1,822
+638
| +54% | +$50.4K | 0.01% | 739 |
|
|
2019
Q4 | $103K | Buy |
1,184
+389
| +49% | +$31.4K | 0.01% | 932 |
|
|
2019
Q3 | $59K | Buy |
+795
| New | +$63.6K | ﹤0.01% | 1293 |
|
|
2019
Q1 | $2K | Sell |
35
-1,726
| -98% | -$83.1K | ﹤0.01% | 2098 |
|
|
2018
Q4 | $58K | Buy |
1,761
+96
| +6% | +$3.51K | ﹤0.01% | 1520 |
|
|
2018
Q3 | $87K | Buy |
1,665
+1,100
| +195% | +$43.8K | ﹤0.01% | 1573 |
|
|
2018
Q2 | $18K | Buy |
+565
| New | +$15.7K | ﹤0.01% | 2533 |
|
|
2016
Q2 | – | Sell |
-35
| Closed | -$2K | – | 3994 |
|
|
2016
Q1 | $2K | Buy |
+35
| New | +$502 | ﹤0.01% | 2097 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
IFP Advisors's NVCR Position: Q1 2026 in Review
IFP Advisors reduced its NovoCure (NVCR) stake by 70% in Q1 2026, selling an estimated $2.15K and leaving 74 shares worth $807. The position accounts for ﹤0.01% of the portfolio, ranked #4283.
IFP Advisors first reported a position in NVCR in Q1 2016 and has held it in 32 quarters since. The position peaked at $449K in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- IFP Advisors held 74 shares of NovoCure worth $807 as of Q1 2026.
- IFP Advisors sold 172 NovoCure shares in Q1 2026, an estimated $2.15K.
- NovoCure made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #4283 holding.
- IFP Advisors first reported a position in NovoCure in Q1 2016 and has held it in 32 quarters since.
- IFP Advisors's NovoCure position peaked at $449K in Q2 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.